Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-003011-38
    Sponsor's Protocol Code Number:20130232
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-11-16
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-003011-38
    A.3Full title of the trial
    A Phase 1b/3 Multicenter, Randomized, Open-label Trial of Talimogene Laherparepvec in combination with Pembrolizumab for theTreatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Ensayo Clínico abierto, randomizado, multicéntrico fase 1b/3 de
    Talimogene Laherparepvec en combinación con Pembrolizumab para el
    tratamiento de pacientes con Carcinoma de Células Escamosas de Cabeza y
    Cuello Metastásico o Recurrente
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Pembrolizumab With or Without Talimogene Laherparepvec in Squamous Cell Carcinoma of the Head and Neck
    Pembrolizumab con o sin Talimogene Laherparepvec en Carcinoma de Células Escamosas de Cabeza y Cuello
    A.4.1Sponsor's protocol code number20130232
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAmgen Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAmgen Inc.
    B.4.2CountryUnited States
    B.4.1Name of organisation providing supportMerck Sharp and Dohme International GmbH
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAmgen (EUROPE) GmbH
    B.5.2Functional name of contact pointIHQ medical Info-Clinical Trials
    B.5.3 Address:
    B.5.3.1Street AddressDammstrasse 23, P.O. Box 1557
    B.5.3.2Town/ cityZug
    B.5.3.3Post codeCH-6300
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number+34900 850 153
    B.5.6E-mailMedinfoInternational@amgen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTalimogene Laherparepvec
    D.3.2Product code AMG 678
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntralesional use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTalimogene laherparepvec
    D.3.9.2Current sponsor codeAMG 678
    D.3.9.3Other descriptive nameTALIMOGENE LAHERPAREPVEC
    D.3.9.4EV Substance CodeSUB130338
    D.3.10 Strength
    D.3.10.1Concentration unit PFU/ml plaque forming unit(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10.6
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product Yes
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Yes
    D.3.11.3.5.1CAT classification and reference numberClassified as a Gene Therapy Medicinal Product EMA/CAT/451866/2012
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTalimogene Laherparepvec
    D.3.2Product code AMG 678
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntralesional use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTalimogene laherparepvec
    D.3.9.2Current sponsor codeAMG 678
    D.3.9.3Other descriptive nameTALIMOGENE LAHERPAREPVEC
    D.3.9.4EV Substance CodeSUB130338
    D.3.10 Strength
    D.3.10.1Concentration unit PFU/ml plaque forming unit(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10.8
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product Yes
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Yes
    D.3.11.3.5.1CAT classification and reference numberClassified as a Gene Therapy Medicinal Product EMA/CAT/451866/2012
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Keytruda
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Sharp & Dohme Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameKeytruda
    D.3.2Product code L01XC18
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPEMBROLIZUMAB
    D.3.9.1CAS number 1374853-91-4
    D.3.9.2Current sponsor codeMK-3475
    D.3.9.3Other descriptive namePembrolizumab
    D.3.9.4EV Substance CodeSUB167136
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Metastatic Squamous Cell Carcinoma of the Head and Neck
    Carcinoma de células escamosas de cabeza y cuello
    E.1.1.1Medical condition in easily understood language
    Head and Neck Cancer
    Cáncer de Cabeza y Cuello
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level PT
    E.1.2Classification code 10060121
    E.1.2Term Squamous cell carcinoma of head and neck
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in subjects with SCCHN.

    Phase 3: To evaluate the efficacy, as assessed by PFS and OS, of treatment with talimogene laherparepvec in combination with pembrolizumab, as compared to pembrolizumab alone.
    Fase 1b: evaluar la seguridad, valorada mediante la incidencia de la toxicidad limitante de la dosis (TLD), de talimogene laherparepvec en combinación con pembrolizumab en sujetos con CCECC recurrente o metastásico.
    Fase 3: evaluar la eficacia, valorada mediante la supervivencia libre de progresión (SLP)
    (evaluación de la respuesta mediante un examen central enmascarado, utilizando los
    criterios de evaluación de la respuesta en tumores sólidos [RECIST] 1.1) y la supervivencia global (SG), del tratamiento con talimogene laherparepvec en combinación con pembrolizumab, en comparación con pembrolizumab solo.
    E.2.2Secondary objectives of the trial
    Phase 1b
    ? To evaluate the efficacy of talimogene laherparepvec in combination with Pembro as assessed by:
    ? ORR, BOR, DOR,DCR, PFS
    ? OS
    ? To evaluate the safety of T-Vec in combination with pembrolizumab as assessed by incidence of AEs and clinical laboratory abnormalities

    Phase 3
    ? To evaluate the efficacy of talimogene laherparepvec in combination with pembrolizumab, as compared to pembrolizumab alone, as assessed by:
    - ORR, BOR; DOR, and DCR
    - PFS
    - 1-year, 2-year, and 3-year survival
    ? To evaluate the safety of talimogene laherparepvec in combination with pembrolizumab, as compared to pembrolizumab alone, as assessed by incidence of AEs and clinical laboratory abnormalities
    Fase 1b
    Evaluar la eficacia de talimogene laherparepvec en combinación con pembrolizumab,valorada mediante:
    -TRO,MRG,DR,TCE, SLP
    - SG
    -Evaluar la seguridad de talimogene laherparepvec en combinación con pembrolizumab, valorada mediante la incidencia de acontecimientos adversos y anomalías en la analítica clínica.
    Fase 3
    Evaluar la eficacia de talimogene laherparepvec en combinación con pembrolizumab, en comparación con pembrolizumab en monoterapia, valorada mediante:
    -TRO, MRG, DR y TCE).
    -SLP
    -Supervivencia a 1 año, 2 años y 3 años.
    Evaluar la seguridad de talimogene laherparepvec en combinación con pembrolizumab,
    en comparación con pembrolizumab en monoterapia, valorada mediante la incidencia de acontecimientos adversos y anomalías clínicas.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -Male or female age ? 18 years with histologically confirmed diagnosis of metastatic or recurrent SCCHN. Disease must be unsuitable for curative surgical resection and must not be amenable to curative radiotherapy.

    -Disease must have progressed after treatment with a platinum-containing regimen

    -Subject must be candidate for intralesional therapy administration defined as one or more of the following:
    At least 1 injectable cutaneous, subcutaneous, or nodal SCCHN tumor ? 10 mm in longest diameter
    Multiple injectable SCCHN tumorsthat in aggregate have a longest diameter of ? 10 mm

    -Subject must have radiographically measurable disease

    -ECOG performance status of 0 or 1

    -Adequate organ function determined within 14 days prior to enrollment

    -Phase 3: Subject has a tumor sample and no systemic therapy given since the biopsy or newly obtained biopsy from the primary or metastatic lesion that is adequate for PD-L1 assessment prior to randomization

    -Phase 3: Have results from local testing of HPV of tumor specimen for oropharyngeal cancer defined as p16 IHC testing using the CINtec® assay and a 70% cutoff point

    -Phase 1b: Subject has a tumor sample and no systemic therapy given since biopsy OR be willing to undergo newly obtained biopsy prior to the first dose of investigational product
    - Hombre o mujer ? 18 años en el momento de proporcionar el consentimiento
    informado.
    -La enfermedad debe haber progresado después del tratamiento con un régimen con contenido de platino
    -El sujeto debe ser candidato a la administración de un tratamiento intralesional definido como uno o más de los siguientes:
    al menos 1 lesión tumoral de CCECC cutánea, subcutánea o ganglionar inyectable de ? 10 mm de diámetro máximo.
    múltiples lesiones tumorales de CCECC inyectables que en conjunto tienen un diámetro máximo de ? 10 mm.
    -El sujeto debe presentar una enfermedad medible radiográficamente
    -Estado funcional ECOG de 0 o 1.
    -Función orgánica adecuada determinada durante los 14 días previos a la inclusión.
    -Fase 3: dispone de resultados de un análisis de VPH en el laboratorio local con una muestra de cáncer orofaríngeo definido como un análisis de IHC p16 con el empleo del ensayo CINtec® y un valor de corte del 70%.
    -Fase 1b: el sujeto dispone de una muestra tumoral fijada en formol e incluida en parafina (muestra tumoral de archivo obtenida en un plazo de 3 meses antes del día 1 y sin haber utilizado un tratamiento sistémico después de la
    biopsia) O está dispuesto a someterse a una nueva biopsia antes de la primera dosis del producto en investigación (día 1).
    -Para más información o criterios adicionales de inclusión, ver el prtocolo
    E.4Principal exclusion criteria
    ? Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis, primary nasopharyngeal carcinoma

    ? Subject at risk of airway compromise in the event of postinjection tumor swelling/inflammation based on investigator judgment

    ? Greater than three lines of prior therapy for current malignancy and/or metastatic disease (Phase 3)

    ? History of other malignancy within the past 3 years, evidence of active, non-infectious pneumonitis, history of interstitial lung disease (ILD)

    ? Prior therapy with talimogene laherparepvec, pembrolizumab, other anti-PD-1, any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathway

    ? History or evidence of active autoimmune disease that has required systemic treatment in past 2 years, evidence of clinically significant immunosuppression

    ? Prior or active herpetic infection, require treatment with an antiherpetic drug, other than intermittent topical use

    ? Prior cancer therapy or major surgery within 28 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to enrollment.
    - El sujeto presenta metástasis activas conocidas en el sistema nervioso central (SNC) y/o meningitis carcinomatosa.
    - Carcinoma nasofaríngeo primario.
    - Sujeto con riesgo de un compromiso de las vías aéreas en el caso de que se produjera una tumefacción/inflamación tras la inyección, según el criterio del investigador.
    - Tratamiento previo con 3 o más regímenes sistémicos administrados para una enfermedad recurrente y/o metastásica (estudio de fase 3).
    - Antecedentes de otros tumores malignos en los últimos 3 años, con las excepciones siguientes:
    Tumor maligno tratado con intención curativa, sin presencia de
    enfermedad activa confirmada, que no haya recibido quimioterapia durante ? 3 años antes de la inclusión y que el médico tratante considere de bajo riesgo de recurrencia.
    Cáncer de piel no melanomatoso tratado adecuadamente sin evidencia de enfermedad en el momento de la inclusión.
    Carcinoma cervical in situ tratado adecuadamente sin evidencia de enfermedad en el momento de la inclusión.
    Carcinoma ductal de mama in situ tratado adecuadamente sin evidencia de enfermedad en el momento de la inclusión.
    Neoplasia intraepitelial prostática sin evidencia de cáncer de próstata en el momento de la inclusión.
    Carcinoma superficial o in situ de vejiga tratado adecuadamente sin evidencia de enfermedad en el momento de la aleatorización.
    -Evidencia indicativa de una neumonitis no infecciosa activa.
    -Antecedentes de enfermedad pulmonar intersticial (EPI).
    -Tratamiento previo con talimogene laherparepvec, pembrolizumab, otros fármacos anti-PD-1, cualquier otro anticuerpo o fármaco específicamente dirigido a la coestimulación de linfocitos T o la vía del punto de control
    inmunitario.
    -Antecedentes o evidencia indicativa de una enfermedad autoinmune activa
    que haya requerido tratamiento sistémico en los 2 últimos años (es decir, con el empleo de fármacos modificadores de la enfermedad, corticosteroides o fármacos inmunosupresores).
    -Lesiones cutáneas herpéticas activas o complicaciones previas por infección herpética (p. ej., queratitis o encefalitis herpética).
    -Requerir tratamiento intermitente o crónico con un fármaco antiherpético (p. ej., aciclovir) que no sea el uso tópico intermitente.
    -Antecedentes de uso de quimioterapia, radioterapia, tratamiento biológico
    para el cáncer o cirugía mayor en los 28 días previos a la inclusión o no haberse recuperado de un acontecimiento adverso de grado 1 o mejor de los criterios CTCAE causado por el tratamiento del cáncer administrado más de 28 días antes de la inclusión.
    -Para más información o criterios adicionales de exclusión, ver el prtocolo
    E.5 End points
    E.5.1Primary end point(s)
    Phase 1b:
    ? Subject incidence of DLT

    Phase 3:
    ? PFS
    ? OS
    Fase 1b
    -Incidencia en los sujetos de TLD.
    Fase 3
    -SLP (evaluación de la respuesta mediante un examen central enmascarado según los criterios RECIST 1.1 convencionales).
    -SG.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Phase 1b: The DLT evaluation period is 6 weeks from the initial administration of study treatment.

    Phase 3: Primary analysis for PFS and OS will be event-driven.
    Fase 1b:El periodo de evaluación de TLD es 6 semanas desde la administración inicial del tratamiento.
    Fase 3: Un Análisis Principal para SLP y SG vendrá dado por los acontecimientos observados
    E.5.2Secondary end point(s)
    Phase 1b:
    ? ORR (CR+PR), BOR, DOR, DCR, and PFS (response evaluation by investigator using irRECIST)
    ? OS
    ? Subject incidence of treatment-emergent and treatment-related adverse events and clinical laboratory abnormalities.

    Phase 3:
    ? ORR, BOR; DOR, and DCR (response evaluation by blinded central assessment using conventional RECIST 1.1 and by investigator using irRECIST)
    ? PFS (response evaluation by investigator using irRECIST)
    ? 1-year, 2-year, and 3-year survival
    ? Subject incidence of treatment-emergent and treatment-related adverse events
    Fase 1b
    -TRO (respuesta completa [RC]+ respuesta parcial [RP]), MRG, DR, TCE y SLP (evaluación de la respuesta por parte del investigador con el empleo de los criterios irRECIST).
    -SG.
    -Incidencia en los sujetos de acontecimientos adversos que aparecen durante el tratamiento y relacionados con el tratamiento (todos los acontecimientos adversos,
    acontecimientos adversos de grado ? 3, acontecimientos adversos graves, acontecimientos adversos mortales, acontecimientos adversos y acontecimientos
    adversos graves que motivan una interrupción definitiva del tratamiento y acontecimientos adversos definidos como acontecimientos de interés) y de anomalías en la analítica clínica.
    Fase 3
    -TRO, MRG, DR y TCE (evaluación de la respuesta mediante un examen central enmascarado con el empleo de los criterios RECIST 1.1 convencionales y por parte del investigador utilizando los criterios irRECIST).
    -SLP (evaluación de la respuesta por parte del investigador con el empleo de los criterios irRECIST).
    -Supervivencia a 1 año, 2 años y 3 años.
    -Incidencia en los sujetos de acontecimientos adversos que aparecen durante el tratamiento y relacionados con el tratamiento (todos los acontecimientos adversos,
    acontecimientos adversos de grado ? 3, acontecimientos adversos graves, acontecimientos adversos mortales, acontecimientos adversos y acontecimientos
    adversos graves que motivan una interrupción definitiva del tratamiento y acontecimientos adversos definidos como acontecimientos de interés).
    E.5.2.1Timepoint(s) of evaluation of this end point
    For the phase 1b part of the study, the primary analysis will occur when the last subject enrolled has had the opportunity to complete the 9-week response assessment.

    For the phase 3 part of the study, the timing for the primary analyses of PFS and OS will be event-driven.

    The final analysis of the study will be conducted after the last subject enrolled in phase 3 has had the opportunity to complete the long-term follow-up.
    -Para la parte de fase 1b del estudio, el análisis principal se realizará cuando el último sujeto incluido haya tenido la oportunidad de completar la evaluación de la respuesta a las 9 semanas.
    -Para la parte de fase 3 del estudio, el momento de realización de los análisis principales en cuanto a la SLP y la SG vendrá dado por los acontecimientos observados.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Biomarker development
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Phase 1b to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT)
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA52
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Canada
    European Union
    South Africa
    Switzerland
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of study for each subject is defined as the date the subject withdraws full consent from the study, completes the safety follow-up visit or final long-term follow-up visit (whichever is later) or death.
    Fin del ensayo: el momento en que el último sujeto es evaluado o recibe una
    intervención para la evaluación en el estudio. Se prevé que esto ocurra 36 meses después de que el último sujeto haya sido aleatorizado en la fase 3
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 490
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 98
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state49
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 490
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-04-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-01-22
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:33:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA